Send a Tweet
Most Popular Choices
Share on Facebook 18 Share on Twitter 1 Printer Friendly Page More Sharing
   H3'ed 3/12/15

FDA Complaint Filed to Require Country of Origin Labeling on Prescription Drugs

By       (Page 2 of 4 pages) Become a premium member to see this article and all articles as one long page.   No comments
Become a Premium Member Would you like to know how many people have read this article? Or how reputable the author is? Simply sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.
Author 84384
Follow Me on Twitter     Message Joel Joseph

Chinese Drugs

China, unlike India, has blocked U.S. efforts to send FDA inspectors. "China is the source of some of the largest counterfeit manufacturing operations that we find globally," said John P. Clark, Pfizer's chief security officer. Prescription drugs are pouring in from China, but U.S. regulators are not ensuring their quality, safety or proper labeling.

Federal regulators have inspected only a fraction of the hundreds of Chinese factories making prescription drugs for the U.S. market, a recent report from the Government Accountability Office says.

Consumers can't tell where imported drugs and dietary supplements are made because country-of-origin labeling laws are not being enforced.

Chinese officials and businesses defend the quality of their products and say their defect rates have been decreasing. But problems with Chinese products keep cropping up -- such as a recent case of Viagra contaminated with a drywall ingredient.

Leo Hepner, an international consultant on food and dietary supplement ingredients, said U.S. consumers did not realize that China now supplied most of the world's vitamin C and antibiotics, along with substantial amounts of other drugs and supplements.

Foreign drug and supplement plants producing for the U.S. market are supposed to meet FDA standards. But the GAO report said the FDA over the past few years had checked only 12 percent of the hundreds of Chinese plants producing pharmaceutical ingredients or finished products for the U.S. market.

The FDA did get to 52 of the plants in China in one year the report said, but that meant it had yet to visit 811 of the 920 Chinese facilities it is supposed to oversee. At the current inspection rate, it will take the FDA more than 15 years to get to the rest of China's plants.

Next Page  1  |  2  |  3  |  4

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).


Must Read 1  
Rate It | View Ratings

Joel Joseph Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Chairman, Made in the USA Foundation, economist and lawyer, author of ten books and hundreds of articles.
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
   (Opens new browser window)

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

The Trumps and Jared Kushner Cheated Their Way into Elite Colleges

Outsourcing Obamacare

Red Nose Day Gives Black Eye to Walgreens and NBC

Shame on Ralph Lauren and the US Open

Great American Products to Buy Labor Day Weekend

U.S Trade Deficit Causes Income Inequality

To View Comments or Join the Conversation: